1 report

Chinese private company SinoMab Bioscience is developing this antibody and has conducted at least two clinical phase I studies, one in non-Hodkgin lymphoma (NHL) (Li, 2012) and one in systemic lupus erythematosus (SLE) (Zhao, 2016).

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • OXIS International, Inc.